Skip to main content
SpringerLink
Log in

Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

De-differentiated thyroid carcinoma is characterized by loss of thyroid-specific functions and properties. The therapeutic options for this type of thyroid cancer are limited and generally not efficient. Recent studies with retinoic acid (RA) have shown that this drug can induce re-differentiation of the thyrocyte and tumor regression after 131I therapy. The aim of the present study was to assess the effects of RA therapy in patients with extensive thyroid tumor involvement, which lost radioiodine uptake ability. A total of 5 patients (1 follicular carcinoma, 3 papillary carcinomas and 1 poorly differentiated carcinoma) were treated with isotretinoin (1.0 to 1.5 mg/kg/day) for 5 weeks and then submitted to radioiodine therapy. Three parameters for assessment of RA effects were established: a) reduction of serum thyroglobulin levels; b) increment of the post-therapeutic dose radioiodine uptake; c) tumor size regression after therapy. All patients completed the treatment and the most frequent side effects were dry skin and lips and hypertriglyceridemia. One patient showed satisfactory response (2 or more of the 3 criteria were reached) and a new cycle of RA was given. In two, just a partial response (1 criterion) was seen and the other patients did not respond. Based on these results, isotretinoin might be an option for de-differentiated thyroid cancer, with low rate of severe side effects, especially when compared with cytotoxic drugs. Aggressive thyroid cancer frequently needs multimodal adjuvant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Rel Canc 2002, 9: 227–47.

    Article  CAS  Google Scholar 

  2. Schlumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med 1998, 338: 297–306.

    Article  CAS  PubMed  Google Scholar 

  3. Goretzki PE, Simon D, Frilling A, et al. Surgical reintervention for differentiated thyroid carcinoma. Br J Surg 1994, 80: 1131–4.

    Google Scholar 

  4. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999, 16: 34–41.

    Article  CAS  PubMed  Google Scholar 

  5. Marcus M, Coulton AM. Fat-soluble vitamins A, K, E. In: Hadman JG, Limbird LE, Gilman AG eds. Goodman and Gilmamn’s The Farmacologic Basis of Therapeutics. New York: Mc Graw Hill, 2000, 1773–92.

    Google Scholar 

  6. Schmutzler C, Winzer R, Maissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of function symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997, 240: 832–8.

    Article  CAS  PubMed  Google Scholar 

  7. Schreck R, Schnieders F, Schmutzler C, et al. Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994, 79: 791–8.

    CAS  PubMed  Google Scholar 

  8. Schmutzler C, Brtko J, Bienert K, Köhrle J. Effects of retinoids and role of retinoic receptor in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabetes 1996, 104 (suppl 4): 16–9.

    Article  CAS  PubMed  Google Scholar 

  9. Van Herle AJ, Agatep ML, Padua DN, et al. Effects of 13-cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro. J Clin Endocrinol Metab 1990, 71: 755–63.

    Article  PubMed  Google Scholar 

  10. Ryu KY, Tong Q, Jhiang SM. Promoter characterization of the human Na+/I- symporter. J Clin Endocrinol Metab 1998, 83: 3247–51.

    CAS  PubMed  Google Scholar 

  11. Schmutzler C, Schmitt TL, Glaser F, Loos U, Köhrle J. The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Mol Cel Endocrinol 2002, 189: 145–55.

    Article  CAS  Google Scholar 

  12. Hoang-Vu C, Schmutzler C, Schwartz I, et al. Effects of retinoic acid on protein expression of CD97 and E-cadherin in the human thyroid cell line FTC-133. J Endocrinol Invest 1998, 21 (suppl): 14.

    Google Scholar 

  13. Havekes B, Schröder van der Elst JP, Van der Pluijim G, et al. Beneficial effects of retinoid acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinomas cell lines. J Endocrinol 2000, 167: 229–38.

    Article  CAS  PubMed  Google Scholar 

  14. Hoang-Vu C, Bull K, Schwartz I, et al. Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab 1999, 84: 1104–9.

    CAS  PubMed  Google Scholar 

  15. Frölich E, Brossart, P, Wahl R. Effects of retinoids on porcine thyrocytes under different culture conditions. Histochem J 2001, 33: 295–304.

    Article  Google Scholar 

  16. Simon D, Köhrle J, Schmutzler C, Mainz K Reiners C, Röher HD. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 1996, 104 (suppl 4): 13–5.

    Article  CAS  PubMed  Google Scholar 

  17. Grünwald F, Menzel C, Bender H, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998, 39: 1903–6.

    PubMed  Google Scholar 

  18. Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998, 22: 569–74.

    Article  CAS  PubMed  Google Scholar 

  19. Schmutzler C, Köhrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000, 10: 393–406.

    Article  CAS  PubMed  Google Scholar 

  20. Simon D, Körber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002, 29: 775–82.

    Article  CAS  PubMed  Google Scholar 

  21. Vu-Dac N, Gervois P, Torra IP, et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. J Clin Invest 1998, 102: 625–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Schlumberger M, Challeton C, Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996, 34: 598–605.

    Google Scholar 

  23. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990, 76: 1704–9.

    CAS  PubMed  Google Scholar 

  24. Lippman SM, Meyskens FL. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Int Med 1987, 107: 499–501.

    Article  CAS  PubMed  Google Scholar 

  25. Enzinger PC, Ilson DH, Saltz LB, Martin LK, Kelsen DP. Phase II clinical trial of 13-cis-retinoic acid and interferon-α-2a in patients with advanced esophageal carcinoma. Cancer 1998, 85: 1213–7.

    Article  Google Scholar 

  26. Kalemkeran GP, Jiroutek M, Ettinger DS, Dorinhi JÁ, Johnson DH, Mabry M. A phase II study of all-transretinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma. Cancer 1998, 83: 1102–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Clementino Fraga Filho University Hospital Laboratory of Endocrine Physiology, Carlos Chagas Filho Institute, Federal University of Rio de Janeiro, Rua Venâncio Flores 368/302, CEP: 22441-090, Rio de Janeiro, Brasil

    S. Mendes Coelho, A. Buescu & M. Vaisman

  2. Nuclear Medicine, Clementino Fraga Filho University Hospital Laboratory of Endocrine Physiology, Carlos Chagas Filho Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brasil

    R. Corbo

  3. National Institute of Cancer, Rio de Janeiro, Brasil

    R. Corbo

Authors
  1. S. Mendes Coelho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Corbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Buescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. P. Carvalho
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Vaisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Vaisman.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coelho, S.M., Corbo, R., Buescu, A. et al. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 27, 334–339 (2004). https://doi.org/10.1007/BF03351058

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03351058

Key-words

Search

Navigation